▲ +75.23% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Spruce Biosciences in the last 3 months. The average price target is $33.75, with a high forecast of $44.00 and a low forecast of $28.00. The average price target represents a 75.23% upside from the last price of $19.26.
The current consensus among 4 investment analysts is to buy stock in Spruce Biosciences.
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company develops tildacerfont, an non-steroidal therapy, which is in Phase IIb clinical trial for adult patients with classic congenital adrenal hyperplasia (CAH) and in Phase II clinical trial in children with classic CAH. It is also developing tildacerfont for females with polycystic ovary syndrome. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was founded in 2014 and is headquartered in Daly City, California.